|Awarded On||August 16, 2017|
|Title||Development of next generation steroid receptor coactivator small molecule inhibitors as novel agents to target therapy-resistant breast cancer|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Bert O'Malley|
Two overarching challenges for current breast cancer treatment are resistance to endocrine therapy in estrogen receptor positive (ER+) breast cancer and tumor metastasis in triple negative breast cancer (TNBC). The objective of this proposal is to develop a novel targeted therapy to address these clinical challenges by inhibiting steroid receptor coactivator 3 (SRC-3) using small molecule inhibitors (SMIs). Our previous work demonstrated that SRC-3 is a master regulator of cellular growth and development which sits at the nexus of many intracellular signaling pathways critical for cancer formation and proliferation. Inhibition of SRC-3 can significantly reduce cancer cell proliferation, moti...